Meropenem-vaborbactam as salvage therapy for ceftazidime-
avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae
producing KPC-31, a D179Y variant of KPC-3

Giusy Tiseo\textsuperscript{a}, Marco Falcone\textsuperscript{a###}, Alessandro Leonildi\textsuperscript{b}, Cesira Giordano\textsuperscript{b}, Simona Barnini\textsuperscript{b}, Gabriele Arcari \textsuperscript{c}, Alessandra Carattoli\textsuperscript{c} and Francesco Menichetti\textsuperscript{a}

\textsuperscript{a} Infectious Diseases Clinic, Azienda Universitaria Ospedaliera Pisana, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; \textsuperscript{b} Microbiology Unit, Azienda Universitaria Ospedaliera Pisana, Pisa, Italy; \textsuperscript{c} Department of Molecular Medicine, “Sapienza” University of Rome, Rome, Italy.

Corresponding author###:

Prof. Marco Falcone

Department of Clinical and Experimental Medicine,

University of Pisa, Pisa, Italy

Fax number +39050996747

Email: marco.falcone@unipi.it

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
ABSTRACT

A 68-year-old man had recurrent bacteremia by *Klebsiella pneumoniae* carbapenemase (KPC)-producing *K. pneumoniae* resistant to ceftazidime-avibactam and cefiderocol. The sequencing of a target region showed that it harbored a KPC-3 variant enzyme (D179Y; KPC-31), which confers resistance to ceftazidime-avibactam and restores meropenem susceptibility. The patient was successfully treated with meropenem-vaborbactam.

**Key words:** KPC, KPC-3, *Klebsiella pneumoniae*, ceftazidime-avibactam resistant, meropenem-vaborbactam
INTRODUCTION

Among MDR organisms, carbapenem-resistant Enterobacterales (CRE) represent a great challenge due to their global spread and limited treatment options. *Klebsiella pneumoniae* carbapenemase (KPC) is the predominant carbapenemase detected among CRE and KPC-producing Enterobacterales are endemic in several countries, including United States, Israel, Latin American countries and Southern Europe (1). Prior to the approval of novel β-lactam/β-lactamase inhibitors, treatment of CRE infection consisted of combination therapy with “agents of last resort”, such as polymyxins, that are associated with high rates of adverse events. The advent of ceftazidime-avibactam (CZA) changed the therapeutic approach to infections caused by CRE (2). Compared to colistin-containing regimens, CZA is associated with reduced risk of 30-day mortality or nephrotoxicity in critically ill patients with *Klebsiella pneumoniae* carbapenemase (KPC)-producing Enterobacterales (3-4). Remarkably, current guidelines recommend CZA as preferred treatment in patients with CRE infections (5). However, CZA, as well as meropenem-vaborbactam (MVB) and imipenem-relebactam (I-R), are not active against metallo-β-lactamase (MBL)-producing strains (2, 6) and other treatment options should be considered. Aztreonam-avibactam (ATM-AVI) and cefiderocol are usually *in vitro* active against MBL-producing Enterobacterales, and preliminary clinical experience is encouraging (2, 7-9).

Resistance to CZA is increasingly reported in KPC-producing strains (10-12). Although it is due to several mechanisms, including alterations of Ompk35 and Ompk36 porins (10-11), β-lactamase-related mutations are the most common causes of CZA resistance (10).

Here we report the clinical use of MVB as salvage therapy for a CZA and cefiderocol-resistant KPC-producing *K. pneumoniae* infection in a critically ill patient.
CASE PRESENTATION

A 68 years old man was admitted to the Azienda Ospedaliera Universitaria Pisana in June 2020 and underwent hip replacement surgery (defined as day 1) due to osteoarthritis. His medical history was significant for hypertension and chronic ischemic cardiomyopathy. He was a past smoker and obese (body mass index 34 kg/m²). According to standard of care at our institution, rectal swabs were performed at admission and periodically during the hospital stay. At admission, the rectal swab culture was negative. A rectal swab taken on day 4 post-surgery, however, led to the detection of a KPC-producing *K. pneumoniae* (KPC-Kp).

On day 7, he developed fever, hypotension and dysuria. Considering the presence of intestinal colonization by KPC-Kp and the presence of septic shock, empirical treatment with CZA 2.5 g administered intravenously (i.v.) over 2 h every 8 h was started. A KPC-producing *K. pneumoniae* was detected from blood and urine specimens by matrix-assisted laser desorption/ionization–time of flight mass spectrometry (MALDI Biotyper, Bruker Daltonics). The KPC-encoding gene was detected by polymerase chain reaction using the GeneXpert System (Cepheid). Routine susceptibility testing was performed according to the laboratory protocol using the SensiTitre system (Thermo Fisher Scientific). Cefiderocol antimicrobial susceptibility testing (AST) was initially assessed by SensiTitre lyophilized broth microdilution (BMD) panel (Thermo Fisher Scientific, USA) and confirmed using iron-depleted cation-adjusted Mueller-Hinton broth (ID-CAMHB) at final iron concentration ≤0.03 μg/mL (13). Minimum inhibition concentrations (MICs) were classified according to breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST).

The KPC-Kp strain was susceptible to colistin, fosfomycin, tigecycline, CZA (MIC =1 mg/L), MVB (MIC= 0,125 mg/L) and cefiderocol (MIC 2 mg/L; Table 1). The minimum bactericidal concentration (MBC) of cefiderocol was 4 mg/L (ID-CAMHB).
Blood cultures obtained on day 7 were negative. Clinical conditions rapidly improved and CZA was discontinued after 14 days of treatment. A delayed healing of the surgical wound was noted. On day 28 (7 days after CZA discontinuation), the patient had fever and worsening clinical conditions. Renal function worsened with an estimated glomerular filtration rate of 46 ml/min/1.73 m². A swab from the wound was obtained and blood cultures were collected. Rapid testing of the blood cultures identified again KPC-producing *K. pneumoniae*, and CZA 1.25 g iv every 8 hours was promptly restarted. Blood and wound cultures grew a new carbapenem-resistant *K. pneumoniae* displaying resistance to CZA (MIC>8 mg/L) and cefiderocol (MIC 16 mg/L and 8 mg/L using ID-CAMHB and Sensititre BMD, respectively), but with restored susceptibility to meropenem (MIC=2 mg/L, see Table1). The strain remained susceptible to MVB (MIC= 0,125 mg/L). Cefiderocol MBC was 16 mg/L using ID-CAMHB.

CZA was discontinued. To evaluate the mechanism of CZA resistance, a polymerase chain reaction and Sanger sequencing of the complete gene and promoter were performed on both urine and blood *K. pneumoniae* isolates. The analysis revealed that the first CZA-susceptible KPC-*Klebsiella pneumoniae* isolate carried the *bla*KPC-3 gene. The second CZA-resistant strain carried the *bla*KPC-31 gene. This latter isolate of *Klebsiella pneumoniae* harbored a KPC-3 variant enzyme with a tyrosine for aspartic acid substitution at Ambler amino acid position 179 (D179Y; KPC-31, accession number MAPH01000113), which is known to confer CZA resistance and restore carbapenem susceptibility (11-12,14-15). Both strains were assigned to Sequence Type 512 by Multi-Locus Sequence Typing (performed according to the Institute Pasteur scheme; https://bigsdb.pasteur.fr/).

At this time, clinicians faced with a clinical dilemma about the most appropriate treatment of this patient considering that: 1) the CZA-resistant KPC-producing isolate was in vitro resistant to cefiderocol; 2) there were concerns about the use of colistin due to high risk of nephrotoxicity; 3) it is not clear whether it is better to use MEM or the combinations of MVB.
We decided to start MVB 1/1 g iv every 8 hours. Clinical conditions improved, with decrease and normalization of inflammatory markers (C-reactive protein and procalcitonin), and healing of the surgical wound. The patient completed a 14-day course of MVB and was discharged. The patient completed a follow-up of 6 months and no relapse occurred.

PATIENT CONSENT STATEMENT

This study was conducted according to the principles stated in the Declaration of Helsinki, and it conforms to standards currently applied in our country. The compassionate use of MVB in this patient was approved by Comitato Etico Area Vasta Nord Ovest (Tuscany, Italy). The patient’s written consent was obtained.

DISCUSSION

Our case highlights two key considerations in the management of KPC-producing \textit{Klebsiella pneumoniae} bacteremia: 1) the development of treatment-emergent CZA resistance after CZA therapy, and 2) the challenging therapeutic option against CZA-resistant KPC-Kp.

The occurrence of CZA-resistance in a patient with KPC-Kp infection treated with CZA may have different explanations, including the failure of CZA monotherapy and the use of inadequate dosages of this antibiotic. The use of CZA as monotherapy or in combination with other \textit{in vitro} active drugs is debated, and a recent network meta-analysis did not detect differences in mortality rates between patients receiving CZA combination therapy or monotherapy (16). Instead, it is not exactly known whether combination therapy might prevent the selection of CZA resistance. Time–kill kinetics showed that combining imipenem plus CZA prevents the emergence of a resistant CZA subpopulation in KPC-3-producing \textit{Klebsiella pneumoniae} (17). Moreover, an animal model of \textit{G. mellonella} infected with mutant KPC-3*179Y*-producing \textit{K. pneumoniae} confirmed that combination therapy was significantly more effective than CZA monotherapy (17). These experimental studies
suggest that selection of CZA-resistant variants of KPC-Kp may be prevented using CZA combined with other antibiotics such as carbapenems. Although we recently showed that recommended dosages of CZA appeared to be adequate to meet the time-dependent pharmacokinetic targets (18), we cannot exclude in our case a CZA underdosing that finally favored the selection of a CZA-resistant strain.

Treatment of CZA-resistant KPC-producing *Klebsiella pneumoniae* is challenging for clinicians. During the last decades, colistin have resurged assuming its role as salvage therapy for otherwise untreatable multidrug-resistant Gram-negative bacilli. However, nephrotoxicity remains a concerning adverse effect of this old drug. Among critically ill patients with bloodstream infections caused by CRE colistin-containing regimens were associated with high risk of 30-day mortality or nephrotoxicity (3-4, 8). Interestingly, KPC-31-producing *Klebsiella pneumoniae* isolates have a restoration of carbapenem susceptibility, suggesting the potential therapeutic usefulness of these drugs (12, 19). The use of carbapenem-monotherapy in patients with KPC-Kp with restored susceptibility to meropenem remains debated. As previously reported in CZA-resistant KPC-3-variant, sublethal meropenem concentrations may select *in vitro* meropenem-resistant variants (20). Double carbapenem therapy demonstrated activity against colistin-resistant KPC-producing *K. pneumoniae* (21), but it has not been evaluated in patients with infections due to CZA-resistant KPC variants. Clinical data addressing this question are lacking and further studies are warranted to clarify this clinical unmet need.

Other new beta-lactam/beta-lactamase inhibitors such as I-R and MVB may represent an alternative option in patients with CZA-resistant KPC-producing *K. pneumoniae*. In our case, the CZA-resistant strain was fully susceptible to MVB, and we observed a significant reduction of meropenem MIC (from 2 to 0.125 mg/L) after the addition of vaborbactam. This seems to suggest an enhanced activity of vaborbactam against KPC-31. Data about MVB are limited. MVB therapy has been evaluated in 16 critically ill-patients with KPC- *Klebsiella pneumoniae* infections (22). One of the
isolates produced KPC-31, and this strain was resistant to CZA. Notably, MVB therapy of KPC-31 Klebsiella pneumoniae infection was associated with recurrent infection by MVB non-susceptible strain (the initial MVB MIC was 0.12 μg/mL, while the MIC of the subsequent recurrent isolate was 8 μg/mL). Whole genome sequencing analysis identified an IS5 insertion in the ompK36 promoter of the recurrent isolate that was not present at baseline and that might explain the increase in the MIC values to MVB. The blaKPC on an IncFIA pBK30683-like plasmid that encoded KPC-31 was unchanged, suggesting that the MVB non-susceptibility was independent from production of mutant KPC-31 carbapenemase (22). All these observations support the choice to treat our patient with MVB.

Finally, it should be noted that KPC-producing K. pneumoniae isolated in our patient was resistant to cefiderocol. To the best of our knowledge, resistance to cefiderocol has been not described in KPC-Klebsiella pneumoniae. A recent study showed that out of 51 KPC-3 producing carbapenem-resistant Klebsiella pneumoniae strains all were susceptible to cefiderocol, even if resistant to CZA (23). Further studies investigating resistance mechanism to cefiderocol in KPC-producing Klebsiella pneumoniae are needed.

In conclusion, the spread of Klebsiella pneumoniae harboring KPC-3 variant enzymes, such as KPC-31, that confers resistance to CZA should be carefully monitored. Since these variants are associated with restoration of meropenem susceptibility, MVB - instead of meropenem alone - may be a therapeutic option.
Acknowledgments

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest

MF received grants and/or speaker honoraria from MSD, Angelini, Shionogi, Pfizer, Menarini and Nordic Pharma. FM has participated in advisory board and/or received speaker honoraria from Angelini, Correvio, Merck Sharp & Dohme (MSD), Nordic Pharma, Pfizer, Astellas, Gilead, Bristol-Myers Squibb (BMS), Janssen, ViiV, bioMérieux, Biotest, Becton Dickinson, Pfizer, and Shionogi. Declared conflicts of interest are outside the submitted work and did not affect scientific objectivity of this study. The other authors have none to declare.
REFERENCES

1. Falcone M, Russo A, Iacovelli A, et al. Predictors of outcome in ICU patients with septic shock caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*. Clin Microbiol Infect. 2016;22:444–50.

2. Falcone M, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016;71:2713-22

3. Falcone M, Bassetti M, Tiseo G, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing *Klebsiella pneumoniae*. Crit Care. 2020;24:29.

4. Karaiskos I, Daikos GL, Gkoufa A, et al. Ceftazidime/avibactam in the era of carbapenemase-producing *Klebsiella pneumoniae*: experience from a national registry study. J Antimicrob Chemother. 2021;76:775-783.

5. Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and *Pseudomonas aeruginosa* with difficult-to-treat resistance (DTR- *P. aeruginosa*). Clin Infect Dis. 2020 Oct 27:ciaa1478.

6. Falcone M, Mezzatesta ML, Perilli M, et al. Infections with VIM-1 metallo-beta-lactamase-producing *Enterobacter cloacae* and their correlation with clinical outcome. J Clin Microbiol. 2009;47:3514-9.

7. Falcone M, Tiseo G, Antonelli A, et al. Clinical features and outcomes of bloodstream infections caused by New Delhi Metallo-β-Lactamase-producing Enterobacterales during a regional outbreak. Open Forum Infect Dis. 2020;7(2):ofaa011.

8. Falcone M, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL-producing Enterobacterales. Clin Infect Dis. 2020 May 19:ciaa586.

9. Falcone M, Tiseo G, Nicastro M et al. Cefiderocol as rescue therapy for *Acinetobacter baumannii* and other carbapenem-resistant Gram-Negative infections in ICU patients. Clin Infect Dis. 2020:ciaa1410.

10. Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020 Sep;22:18-27.
11. Haidar G, Clancy CJ, Shields RK et al. Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases. Antimicrob Agents Chemother 2017;61:e02534-16.
12. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: a case report and review of literature. Open Forum Infect Dis. 2017;4:ofx101.
13. Hackel MA, Tsuji M, Yamano Y, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 2018; 62: e01968-17.
14. Gaibani P, Lombardo D, Foschi C, Re MC, Ambretti S. Evaluation of five carbapenemase detection assays for Enterobacteriaceae harbouring blaKPC variants associated with ceftazidime/avibactam resistance. J Antimicrob Chemother, 2020;75:2010-2013
15. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev. 2020;34:e00115-20
16. Fiore M, Alfieri A, Di Franco S, et al. Ceftazidime-Avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis. Antibiotics (Basel) 2020;9:388.
17. Göttig S, Frank D, Mungo E, Nolte A, Hogardt M, Besier S, Wichelhaus TA. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. J Antimicrob Chemother. 2019;74:3211-3216
18. Falcone M, Menichetti F, Cattaneo D, Tiseo G, Baldelli S, Galfo V, Leonildi A, Tagliaferri E, Di Paolo A, Pai MP. Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. J Antimicrob Chemother. 2020 Dec 30;dkaa549.
19. Shields RK, Potoski BA, Haidar G, Hao B, Dui Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH. 2016. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63:1615–1618
20. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases. Antimicrob Agents Chemother. 2017;61:e00079-17
21. Ceccarelli G, Falcone M, Giordano A, Mezzatesta ML, Caio C, Stefani S, Venditti M. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated
pneumonia due to colistin-resistant KPC-producing *Klebsiella pneumoniae*. Antimicrob Agents Chemother. 2013;57:2900-1.

22. Shields RK, McCreary EK, Marini RV, Kline EG, Jones CE, Hao B, Chen L, Kreiswirth BN, Doi Y, Clancy CJ, Nguyen MH. Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2020;71:667-671

23. Delgado-Valverde M, Conejo MDC, Serrano L, Fernández-Cuenca F, Pascual Á. Activity of cefiderocol against high-risk clones of multidrug-resistant *Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia*. J Antimicrob Chemother. 2020;75:1840-1849.
Table 1. Antibiotic susceptibility of the clinical isolates of KPC-producing *K. pneumoniae* (first KPC-3 and recurrent KPC-31-D179Y isolate).

| Antibiotic                      | First isolate KPC-3 | Recurrent isolate KPC-31, D179Y |
|---------------------------------|---------------------|----------------------------------|
| **MIC, mg/L (interpretation)**  |                     |                                  |
| Amoxicillin/clavulanate         | >16 (R)             | >16 (R)                          |
| Piperacillin/tazobactam         | >128 (R)            | >128 (R)                         |
| Ceftriaxone                     | >4 (R)              | >4 (R)                           |
| Ceftazidime                     | >128 (R)            | >128 (R)                         |
| Cefepime                        | >32 (R)             | >32 (R)                          |
| Ertapenem                       | >1 (R)              | >1 (R)                           |
| Imipenem                        | >16 (R)             | <0.25 (S)                        |
| Meropenem                       | >64 (R)             | 2 (S)                            |
| Fosfomycin                      | <16 (S)             | >128 (R)                         |
| Amikacin                        | >16 (R)             | >16 (R)                          |
| Gentamicin                      | 4 (I)               | 4 (I)                            |
| Ciprofloxacin                   | >2 (R)              | >2 (R)                           |
| Tigecycline                     | 0.5 (S)             | 0.5 (S)                          |
| Colistin                        | 0.5 (S)             | 0.5 (S)                          |
| Ceftazidime-avibactam           | 1 (S)               | >8 (R)                           |
| Cefiderocol                     | 2 (S)*              | 16 (R)*                          |
|                                 | 2 (S)**             | 8 (R)**                          |
| Meropenem-vaborbactam           | 0.125 (S)           | 0.125 (S)                        |

* Iron depleted Mueller Hinton Broth  
** Broth microdilution (Sensititre)